Novo Nordisk (Denmark) is a healthcare company and a world leader in diabetes care. The company has 87 years of experience in insulin manufacturing and marketing since 1922 and currently it markets its products in 179 countries. Novo Nordisk (Denmark) has a proven track record and expertise producing biotechnological and other hi-tech products. The company has international production facilities in six countries and now it is on the way of expanding its production facility in Bangladesh and thus holding an agreement of technology transfer for insulin with Eskayef Pharmaceuticals Ltd. This insulin manufacturing technology transfer is a significant undertaking and will certainly help to provide process efficiency and control and maintain product quality in Bangladesh.
Eskayef Pharmaceuticals Ltd. is one of the leading healthcare solution providers in Bangladesh with faster expansion in global horizon including Europe, Central America, Africa and Asian countries. Since its inception, Eskayef is carrying the heritage and legacy of multinational company. The company is now manufacturing and marketing a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products. Over the years, the company has established itself as the most trusted, quality driven and information based company to the doctors’ community.